Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $4.5 billion of committed capital.
Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $4.5 billion of committed capital.
Basilea Announces CHF 75 Million Senior Secured Loan Agreement with Athyrium
RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing
uMotif Expands Leadership Team to Support Growth in US and EU Markets
uMotif Announces $25.5m Investment from Fund Managed by Athyrium Capital Management
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management
Humana and Longevity Health Partner to Expand Access to Special Needs Plans for Medicare Beneficiaries
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection